Funding
WS, AKC, Hashimoto, MH, Jonathan R, WL
HASHIMOTO, KIDNEY DISEASES, KIDNEY, SECONDARY, CARDIOVASCULAR DISEASES, HEART, DER, BROWN
EMPA-KIDNEY is sponsored by Boehringer Ingelheim, with grant funding provided to
the University of Oxford from Boehringer Ingelheim and Eli Lilly. EMPA-KIDNEY is
coordinated by the MRC Population Health Research Unit at the University of
Oxford, which is part of the Clinical Trial Service Unit and Epidemiological
Studies Unit (CTSU), Nuffield Department of Population Health. Funding is
provided to CTSU by the UK Medical Research Council (MRC) (Ref: MC_UU_00017/3),
the British Heart Foundation, NIHR Biomedical Research Council, and Health Data
Research (UK). WGH was funded by an MRC–Kidney Research UK Professor
David Kerr Clinician Scientist Award (MR/R007764/1).
NS, RH, CB and WGH proposed and developed the analyses, had full access
to the data, wrote the first draft and have final responsibility for the
publication. NS led analyses with JRE, and replication by SS. All authors
contributed to data interpretation and manuscript review.
Natalie Staplin*, Richard Haynes*, Parminder K Judge, Christoph Wanner,
Jennifer B Green, Jonathan R Emberson, David Preiss, Kaitlin J Mayne, Sarah YA
Ng, Emily Sammons, Doreen Zhu, Michael Hill, Will Stevens, Karl Wallendszus,
Susanne Brenner, Alfred K Cheung, Zhi-Hong Liu, Jing Li, Lai Seong Hooi, Wen
Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Cherney, Aldo P
Maggioni, Roberto Pontremoli, Rajat Deo, Shinya Goto, Xavier Rossello, Katherine
R Tuttle, Dominik Steubl, Michaela Petrini, Svenja Seide, Martin J Landray,
Colin Baigent*, William G Herrington** Equal contributionsAffiliations of the Writing Committee are as follows: Clinical Trial
Service Unit and Epidemiological Studies Unit, Nuffield Department of Population
Health, University of Oxford, UK (*also part of the Medical Research Council
Population Health Research Unit at the University of Oxford): NS*, RH*, PJ, KJM,
JRE*, DP*, SYAN, AJR, ES, DZ, WS, KW, MH*, MJL*, CB*, WGH*. University Clinic of
Würzburg, Germany: CW & SB. Duke Clinical Research Institute,
Durham, North Carolina, US: JBG. University of Utah, Salt Lake City, US: AKC.
Boehringer Ingelheim International GmbH: SJH, DS. Elderbrook Solutions GmbH on
behalf of Boehringer Ingelheim Pharma GmbH & Co.KG: DM. Vth Department of
Medicine, University Medical Center Mannheim, University of Heidelberg,
Mannheim, Germany: SJH. Department of Nephrology, Hospital Rechts der Isar,
Technical University of Munich, Germany: DS. National Clinical Research Center
of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine,
Nanjing, China: ZHL. Fuwai Hospital, Chinese academy of Medical Sciences,
National Center for Cardiovascular Diseases, Beijing, China: JL. Hospital
Sultanah Aminah, Johor Bahru, Malaysia: LSH & WL. The University of Tokyo
School of Medicine/Toranomon Hospital: TK. The University of Tokyo School of
Medicine, Tokyo, Japan: MN. Tokai University School of Medicine, Isehara, Japan:
SG. University of British Columbia, Vancouver, Canada: AL. University of
Toronto, Canada: DC. Università degli Studi and IRCCS Ospedale
Policlinico San Martino di Genova, Italy: RP. ANMCO Research Center, Florence,
Italy: APM. University of Pennsylvania Perelman School of Medicine,
Philadelphia, US: RD. Providence Health Care and University of Washington, US:
KRT. Hospital Universitario Son Espases, Health Research Institute of the
Balearic Islands (IdISBa), Universitat Illes Balears (UIB), Palma de Mallorca,
Islas Baleares, Spain: XR.

Colin Baigent (co-Chair), Martin J. Landray (co-Chair), Christoph Wanner
(Deputy Chair), William G. Herrington (Chief Investigator), Richard Haynes
(co-Principal Investigator), Jennifer B. Green, Sibylle J. Hauske*, Martina
Brueckmann*, Mark Hopley* (Previous members: Maximillian von-Eynatten* &
Jyothis George*).
Executive Committee members plus National Representatives: Susanne
Brenner (Germany); Alfred K. Cheung (United States); David Preiss (United
Kingdom); Zhihong Liu, Jing Li (China); Laiseong Hooi, Wen Liu (Malaysia);
Takashi Kadowaki, Masaomi Nangaku (Japan); Adeera Levin, David Cherney (Canada);
Roberto Pontremoli, Aldo Pietro Maggioni (Italy); plus statistician members:
Natalie Staplin, Jonathan Emberson, Stefan Hantel*; plus other expert members:
Shinya Goto, Rajat Deo, Katherine Tuttle. Non-voting members: Parminder Judge,
Kaitlin J. Mayne, Michael Hill, Sarah Y.A. Ng, Xavier Rossello, Emily Sammons,
Doreen Zhu. * denotes a Boehringer Ingelheim employee.
Peter Sandercock (Chair), Rudolf Bilous, Charles Herzog, Paul Whelton,
Janet Wittes, Derrick Bennett (non-voting statistician).
Andy Burke, Richard Brown, Rejive Dayanandan, Lucy Fletcher, Hannah
Gosling, Emily Harding, Richard Haynes, William G. Herrington, Parminder Judge,
Carol Knott, Ryonfa Lee, Kevin Murphy, Yanru Qiao, Rachel Raff, Hui Yu.
YanRu Qiao (UK); Vladimir Cejka, Marcela Fajardo-Moser (Germany); Andrea
Lorimer, Donata Lucci (Italy); Anita Hepditch (US); Amanda Axler (Canada);
Peiling Chen, Dai Hao (China), Cheng Beng Goh, Sarojini Sivanandam (Malaysia);
Akiko Hashimoto, Sawako Maeno, Wakako Negoro, Aiko Tomita, Morisaki Tomoko
(Japan).
See 
This paper has not been published previously in whole or part. CTSU
(which employs RH) has a staff policy of not accepting honoraria or other
payments from the pharmaceutical industry, except for the reimbursement of costs
to participate in scientific meetings (see 
The EMPA-KIDNEY Steering Committee has developed a comprehensive
analysis plan for subsidiary analyses which will be presented in future
scientific presentations and publications. Data will be made available to other
researchers in 2024. Application is by email to
In adherence with the Boehringer Ingelheim Policy on Transparency and
Publication of Clinical Study Data, scientific and medical researchers can
request access to clinical study data after publication of the primary
manuscript and secondary analyses in peer-reviewed journals and regulatory and
reimbursement activities are completed, normally within 1 year after the
marketing application has been granted by major Regulatory Authorities.
Researchers should use the 
For the purpose of open access, the authors have applied a Creative
Commons Attribution (CC BY) licence to any Author Accepted manuscript version
arising.